| Bioactivity | PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC50 values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR[1]. |
| Sequence | Ala-Cys-Ala-Glu-Leu-Val-Asp-Asn-Ala-Val-Ala-Ile-Gly-Gly-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys(AEEA-AEEA-γGlu-C18 diacid)-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Ala-Arg-Asn-Arg-Asn-Asn-Ile-Ala |
| Shortening | ACAELVDNAVAIGGQGTFTSDYS-K(AEEA-AEEA-γGlu-C18 diacid)-YLDSRRAQDFVQWLMNTARNRNNIA |
| Formula | C269H426N74O88S2 |
| Molar Mass | 6168.83 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lei Zhao, et al. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects. Org Biomol Chem. 2019, 17, 33. |